Clinical trial
Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders
NCT00132418 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00132418 |
|---|---|
| Title | Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders |
| Official title | Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders |
| Lead sponsor | Amgen, Industry |
| Collaborators | Immunex Corporation Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Enbrel, Placebo |
| Enrollment | 564 |
| Start date | Apr 1, 2000 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Aug 22, 2005 |
| Last update posted | Jan 21, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: